TickerFacts.

Company research / CRL

Charles River Laboratories International, Inc. (CRL)

Build a valuation ↗↓ Download CSV

SEC name CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · CIK 0001100682 · NYSE · Services-Commercial Physical & Biological Research

  • Sector Services
  • Fiscal year ends around Dec 27

For the year ended 2025-12-27, Charles River Laboratories International, Inc. reported revenue of $4.02B. Revenue fell 0.9% from the prior annual period. Over the twelve months to 2026-06-27, revenue was $4.00B.

Key ratios (year ended 2025-12-27)

0.6%
Operating margin
-3.5%
Net margin
-4.5%
Return on year-end equity
-0.9%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-07

Headquarters locality: Wilmington · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-27 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-27		2025-12-272024-12-282023-12-302022-12-312021-12-252020-12-262019-12-282018-12-292017-12-302016-12-31
Revenue$4.00B$4.02B$4.05B$4.13B$3.98B$3.54B$2.92B$2.62B$2.27B$1.86B$1.68B
Cost of Revenuen/an/an/an/an/an/an/an/an/a$289.67M$277.03M
Gross Profit (computed)n/an/an/an/an/an/an/an/an/a$1.57B$1.40B
Operating Income$90.14M$25.16M$227.35M$617.26M$650.98M$589.86M$432.73M$351.15M$331.38M$288.28M$237.55M
Depreciation & Amortization$297.88M$403.31M$361.74M$314.12M$303.87M$265.54M$234.92M$198.09M$161.78M$131.16M$126.66M
EBITDA$388.03M$428.47M$589.09M$931.38M$954.85M$855.40M$667.65M$549.25M$493.16M$419.44M$364.21M
Net Income-$236.30M-$142.16M$25.29M$480.37M$492.61M$398.84M$365.31M$254.06M$228.72M$125.45M$156.37M
EPS (Diluted)n/a-$2.91$0.20$9.22$9.48$7.60$7.20$5.07$4.62$2.54$3.23
Total Assets$7.53B$7.14B$7.53B$8.20B$7.60B$7.02B$5.49B$4.69B$3.86B$2.93B$2.71B
Total Liabilities$4.64B$3.92B$4.02B$4.54B$4.58B$4.43B$3.35B$3.03B$2.52B$1.87B$1.86B
Long-Term Debtn/an/an/an/an/an/an/an/a$1.61B$1.09B$1.18B
Shareholders' Equity$2.85B$3.17B$3.47B$3.60B$2.98B$2.54B$2.12B$1.64B$1.32B$1.05B$839.12M
Cash & Equivalents$192.03M$213.77M$194.61M$276.77M$233.91M$241.21M$228.42M$238.01M$195.44M$163.79M$117.63M
Operating Cash Flow$582.15M$737.65M$734.58M$683.90M$619.64M$760.80M$546.58M$480.94M$441.14M$318.07M$316.90M
Capital Expenditures$211.54M$219.15M$232.97M$318.53M$324.73M$228.77M$166.56M$140.51M$140.05M$82.43M$55.29M
Free Cash Flow$370.61M$518.49M$501.61M$365.37M$294.91M$532.03M$380.01M$340.42M$301.09M$235.64M$261.61M
Share Repurchases$324.07M$360.67M$119.17M$24.16M$38.65M$40.71M$23.98M$18.09M$13.85M$106.91M$12.27M
Shares Outstanding47.73M49.22M51.14M51.34M50.94M50.48M49.77M48.94M48.21M47.40M47.36M
Weighted Average Diluted Sharesn/a49.56M51.63M51.45M51.30M51.42M50.61M49.69M49.02M48.56M47.96M
EPS (Basic)n/a-$2.91$0.20$9.27$9.57$7.77$7.35$5.17$4.72$2.60$3.29

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView